Viatris (HAM:VIA) Research & Development: €853 Mil (TTM As of Mar. 2026)


HAM:VIA Viatris Inc HAM:VIA
58 GF Score
Price €14.26
GF Value €9.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Viatris Research & Development?

Viatris HAM:VIA +1.71% 58 Research & Development is €853 Mil as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.77 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Viatris's Research & Development for the three months ended in Mar. 2026 was €215 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €853 Mil.

Viatris  (HAM:VIA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Viatris Research & Development Related Terms

Viatris Research & Development Historical Data

* Premium members only.

The historical data trend for Viatris's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Research & Development Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 602.69 625.12 738.37 772.31 824.88

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 205.35 189.70 213.34 234.59 215.04
HAM:VIA
58GF Score
Viatris Inc HAM:VIA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €853 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €853 Mil mean?
Viatris (HAM:VIA) has a Research & Development of €853 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Viatris and its competitors.
Is Viatris' Research & Development too high?
Viatris' current Research & Development is €853 Mil. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Research & Development compare to NBIX and UTHR?
Viatris' Research & Development of €853 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Viatris and its competitors. Viatris's current Research & Development is €853 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.77, compared to a current price of €14.26 — trading 45.9% above its estimated fair value. The current Research & Development is €853 Mil. Viatris' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Research & Development is €853 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Research & Development: €853 Mil
  • GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score

Get the complete analysis for HAM:VIA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.26
Price
€9.77
GF Value